| 1 |
Antifibrotics and Reduced Mortality in Idiopathic Pulmonary Fibrosis: Immortal Time Bias |
|
|
| Samy Suissa, Karine Suissa |
|
| American Journal of Respiratory and Critical Care Medicine. 2023; 207(1): 105 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 2 |
A Systematic Review of the Prognostic Significance of the Body Mass Index in Idiopathic Pulmonary Fibrosis |
|
|
| Angelo Zinellu, Ciriaco Carru, Pietro Pirina, Alessandro G. Fois, Arduino A. Mangoni |
|
| Journal of Clinical Medicine. 2023; 12(2): 498 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 3 |
Nintedanib and pirfenidone for idiopathic pulmonary fibrosis in King Abdulaziz Medical City, Riyadh: Real-life data |
|
|
| MohammedAyaz Khan, Nahed Sherbini, Sami Alyami, Abdullah Al-Harbi, Majed Al-Ghamdi, Suliman Alrajhi, Rajkumar Rajendram, Hamdan Al-Jahdali |
|
| Annals of Thoracic Medicine. 2023; 18(1): 45 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 4 |
The relative contribution of co-morbidities to health-related quality of life of people with idiopathic pulmonary fibrosis using the Assessment of Quality of Life-8-Dimension multi-attribute utility instrument |
|
|
| Qiang Zheng, Ingrid A. Cox, Barbara de Graaff, Julie A. Campbell, Tamera J. Corte, Ian Glaspole, Vidya Navaratnam, Peter Hopkins, Chris Zappala, Hasnat Ahmad, Ting Zhao, Sacha Macansh, E. Haydn Walters, Andrew J. Palmer |
|
| Quality of Life Research. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 5 |
Real-World Clinical Outcomes Based on Body Mass Index and Annualized Weight Change in Patients with Idiopathic Pulmonary Fibrosis |
|
|
| Joyce S. Lee, Adam Martin-Schwarze, Elizabeth Freiheit, Ben Trzaskoma, Cindy Burg |
|
| Advances in Therapy. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 6 |
Physical activity, exercise capacity and mortality risk in people with interstitial lung disease: a systematic review and meta-analysis |
|
|
| Vânia Rocha, Cátia Paixão, Alda Marques |
|
| Journal of Science and Medicine in Sport. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 7 |
Investigation of clinical predictors of survival in idiopathic pulmonary fibrosis patients: A cohort study in Taiwan |
|
|
| Ching-Min Tseng, Mei-Yin Chen, Chen-Yu Kao, Chi-Wei Tao |
|
| Journal of the Chinese Medical Association. 2022; 85(5): 578 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 8 |
Idiopathic pulmonary fibrosis: Current and future treatment |
|
|
| Daniel S. Glass, David Grossfeld, Heather A. Renna, Priya Agarwala, Peter Spiegler, Joshua DeLeon, Allison B. Reiss |
|
| The Clinical Respiratory Journal. 2022; |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 9 |
Effects of oxygen supplementation in autonomic nervous system function during exercise in patients with idiopathic pulmonary fibrosis and exertional desaturation |
|
|
| Afroditi K. Boutou, Konstantina Dipla, Marieta P. Theodorakopoulou, Katerina Markopoulou, Georgia Pitsiou, Stavros Papadopoulos, Stella Kritikou, Ioannis Stanopoulos, Andreas Zafeiridis |
|
| The Clinical Respiratory Journal. 2021; 15(10): 1088 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 10 |
Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary Fibrosis |
|
|
| Tananchai Petnak, Ploypin Lertjitbanjong, Charat Thongprayoon, Teng Moua |
|
| Chest. 2021; 160(5): 1751 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
| 11 |
Clinical characteristics and outcomes in patients with primary Sjogren's syndrome-associated interstitial lung disease |
|
|
| EsamH Alhamad, JosephG Cal, NuhaN Alrajhi, MuthurajanP Paramasivam, WaleedM Alharbi, Mohammed AlEssa, MohammedA Omair, AmmarC AlRikabi, AhmadA AlBoukai |
|
| Annals of Thoracic Medicine. 2021; 16(2): 156 |
|
| [Pubmed] [Google Scholar] [DOI] |
|
